Latest Breaking News On - Crinetics pharmaceuticals inc - Page 15 : comparemela.com

Profund Advisors LLC Increases Stake in Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX)

Profund Advisors LLC Increases Stake in Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Stephenf betzMarc wilsonBlackrock incJennison associatesExchange commissionJpmorgan chase coMorgan stanleySecurities exchange commissionCrinetics pharmaceuticals profileCrinetics pharmaceuticalsNews ratings for crinetics pharmaceuticals dailyCrinetics pharmaceuticals incJefferies financial groupCrinetics pharmaceuticals price performanceCantor fitzgeraldProfund advisors

Profund Advisors LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX)

Profund Advisors LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Dana pizzutiStephenf betzInvesco ltdJefferies financial groupCantor fitzgeraldCrinetics pharmaceuticals stockJpmorgan chase coCrinetics pharmaceuticals incNorthern trust corpCrinetics pharmaceuticals company profileMorgan stanleyInsider activity at crinetics pharmaceuticalsCrinetics pharmaceuticalsQuarter for crinetics pharmaceuticalsNews ratings for crinetics pharmaceuticals dailyExchange commission

Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc

Steven Cohen (Trades, Portfolio), through Point72 Asset Management, has recently made a notable adjustment in the firm's investment portfolio by reducing its stake in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This trade has altered the firm's portfolio by a -0.09% impact, with CRNX now representing 0.36% of the total portfolio and 5.10% of the firm's holdings in the traded stock.

United statesCrinetics pharmaceuticals incFisher asset managementPharmaceuticals incSteven cohenFinancial strengthProfitability rankGrowth rankMomentum rankAsset managementCrinetics pharmaceuticalsPoint72 asset managementInvestment portfolioMeta platforms incHealthcare sectorsUrrent stock price

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Corey davisNatalie badilloHead of corporate communicationsCrinetics pharmaceuticalsCrinetics pharmaceuticals to report fourth quarterCrinetics pharmaceuticals incLifesci advisorsReport fourth quarterFull yearSci advisors

Cantor Fitzgerald Reaffirms Overweight Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Cantor Fitzgerald Reaffirms Overweight Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stephenf betzMarc wilsonCantor fitzgeraldMorgan stanleyWealth partnersInstitutional investors weigh in on crinetics pharmaceuticalsAnalyst recommendations for crinetics pharmaceuticalsNews ratings for crinetics pharmaceuticals dailyJpmorgan chase coJefferies financial groupCrinetics pharmaceuticals stock performanceSecurities exchange commissionCrinetics pharmaceuticalsJennison associatesCrinetics pharmaceuticals incVictory capital management inc